Eculizumab treatment of atypical hemolytic uremic syndrome

Medicine & Life Sciences

• eculizumab 100%
• Atypical Hemolytic Uremic Syndrome 99%
• Complement C5a 28%
• Complement Membrane Attack Complex 25%
• Orphan Drug Production 14%
• Thrombotic Microangiopathies 12%
• Complement System Proteins 11%
• Therapeutics 10%
• Complement Activation 10%
• Expert Testimony 9%
• Standard of Care 9%
• Drug Resistance 8%
• Liver Transplantation 8%
• Antibody Formation 8%
• Transplantation 7%
• Maintenance 6%
• Retrospective Studies 6%
• Clinical Trials 6%
• Transplants 5%
• Costs and Cost Analysis 5%
• Morbidity 5%
• Recurrence 5%
• Mutation 5%
• Kidney 5%
• Mortality 4%
• Wounds and Injuries 4%
• Child 4%
• Pharmaceutical Preparations 3%
• Genes 3%

Social Sciences

• drug 29%
• orphan 26%
• adolescent 25%
• expert opinions 25%
• Clinical Trials 23%
• morbidity 22%
• activation 21%
• pharmaceutical 20%
• mortality 18%
• candidacy 16%
• costs 12%